Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome (II) Combination in Irinotecan-Resistant Colorectal Cancer
NCT07044921Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2024
- Primary completion
- Jul 2026
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan liposome injection in colorectal cancer (CRC), sponsored by Chinese PLA General Hospital. Started Sep 2024; status: recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07044921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07044921.